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ABBREVIATIONS 
FVC  - Forced vital capacity 
VC          - Vital capacity 
FEV1  - Forced expiratory volume in 1s 
FEV1/FVC - Ratio of FEV1 to FVC 
FEF25-75%   - Forced expiratory flow rate between 25 and   
75% of the VC 
TLC  - Total lung capacity 
RV  - Residual volume 
MMFR - Maximal midexpiratory flow rate 
MIP  - Maximal inspiratory pressure 













               Pulmonary Function Tests involves the measure 
of airflow rates, lung volumes, and the ability of the lung to 
transfer  gas across the alveolar capillary membrane. 
Pulmonary function parameters are very useful  to diagnose 
obstructive lung disease.   Smoking is the most important risk 
factor for chronic obstructive pulmonary disease. 
SMOKING 
               Smoking is major public health problem. Cigarette 
smoke contains more than 40001 compounds of which a few 
toxins have  been studied in detail.  Among the most prevalent 
diseases  with which cigarette smoking has been implicated are 
cancers, chronic obstructive lung disease and atherosclerotic 
cardiovascular disease. 
                      In the respiratory tract smoking predisposes to 
malignant conditions like lung cancer,  laryngeal cancer and 
non-malignant conditions like COPD, sleep apnea, eosinophilic 
granuloma of lung, respiratory bronchiolitis, Goodpature 
syndrome and  pneumothorax. 
                         Smoking is a major risk factor for COPD. The 
risk of COPD is increased 30-fold in smokers. Nearly all 
patients with clinically significant emphysema are smokers. 
Smoking  is the major risk factor for the development of chronic 
bronchitis. 
SPIROMETRY 
                        Spirometry  is a simple method for studying the 
pulmonary function by recording the volume of air movement 
into and out of the lungs. In this test, the subject inhales 
maximally to total lung capacity (TCL) and then exhales as 
rapidly and forcefully as possible into the turbine of spirometer, 
which calculates the flow rates and volume measurements. The 
flow rates can be calculated from the  ‘spirogram’ which is a 
plot of volume versus time, and the volume can be calculated 
from the ‘ Flow – volume tracings‘ which is a plot of airflow 
versus the expired or inspired lung volume. 
 FLOW RATES 
                         Forced vital capacity is the maximal volume of 
gas which can be expired from the lungs  during a forced 
expiration from a position of full inspiration. The FVC can be 
subdivided into forced expiratory volume in first second (FEV1), 
in the second second (FEV2), and in the third second (FEV3). So, 
FEV1, represents the integrated flow over first second of 
expiration and reflects airway narrowing during expiration. It is 
effort independent and normally 70% - 80% of the FVC is 
expired in the first second. This is a useful method to analyze 
the airway obstruction that occurs  in varied pathological 
conditions of  lung.  
                           A more sensitive means of evaluating airway 
obstruction is, to express the forced expired volume as percent 
of vital capacity, abbreviated as FEV1/FVC. This ratio is 
relatively independent of patients restriction of lung volumes. 
Normally it is 70% or greater. 
                      Another way of assessing  airflow obstruction is 
to measure specific flow rates. Peak expiratory flow rate (PEFR) 
is defined as the maximum flow achievable from a forced 
expiration starting at full inspiration with an open glottis. It 
measures the maximum expiratory flow rate over the first ten 
milliseconds. PEFR is reduced in large airway narrowing due to 
asthma, COPD, vocal cord palsy and expiratory muscle 
weakness etc. 
                 Flow from 25 to 75 percent of the total FVC, termed  
FEF25%-75% is another measurement which was originally called 
as Maximal mid-expiratory flow rate (MMER). This is effort – 
independent   and   is   a   very sensitive to airflow obstruction 
in peripheral, small airways, where disease  of chronic airflow 
obstruction  are thought to begin. FEF25%-75% is independent of 
FVC, in otherwords, it is the average flow rate during the 
middle two quarters of the FVC. 
FLOW VOLUMES     
                Flow volume curve, a recording during spirometry, of 
the expiratory flow plotted against expired volume, instead of 
time, resembles a triangular shaped envelope. At the point 
where 25% of vital capacity has been exhaled, this flow rate is 
termed Vmax25 or FEF25%, when 50% of the vital capacity has 
been exhaled is is termed Vmax50 or FEF50% and at 75% of vital 
capacity it is Vmax75 or FEF75% 
                      The inspiratory portion of the curve is helpful in 
distinguishing large airway obstruction which occurs above the 
level of  the thoracic  inlet from obstruction that occur below 
this level. Large airway obstruction above the thoracic inlet 
results in a plateau of the flow rate on  the   inspiratory  portion 
of  the  curve,  while  the  expiratory  portion  in  affected  when  
the  flow  limiting  portion  is  within  the thoracic  cavity.                      
                                               FEF75%   is thought  to  be very 
sensitive to detect early small airway obstruction. In early small 
airway disease, the only abnormality detected may be reduced 
FEF75%  and  FEF50%   with normal  PEFR   and  FEV1. 
 
PATTERNS OF ABNORMAL VENTILATORY CAPACITY 
        FEV1       FVC   FEV1 /FVC 
Obstructive         ↓↓       ↓/ N            ↓ 
Restrictive          ↓        ↓↓            ↑/ N 
 
                    Smoking being the most important risk factor for 
COPD, this study was undertaken to assess the pulmonary 
dysfunction in asymptomatic smokers, so that early  
intervention by smoking cessation would reduce the  disease 
burden of COPD. 











AIM OF STUDY 
1. To evaluate the pulmonary function test parameters in 
asymptomatic smokers. 
2. To compare the spirometric findings in asymptomatic 
smokers to their expected values.  
3. To identify the asymptomatic COPD among smokers, so 
that cessation of smoking would halt their progression. 
4. To identify the degrees of deterioration in PFT.  
5. To correlate the dysfunction with the quantum of 
smoking. 
6. To look into gender differences in the progression of 
disease.   
REVIEW OF LITERATURE 
HISTORICAL PERSPECTIVE 
 Chronic obstructive pulmonary disease (COPD) has been 
defined by the Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) as a disease state characterized by airflow 
limitation that is not fully reversible.    
                          By 1964, the Advisory committee to the 
surgeon general of the unitedstates concluded that cigarette 
smoking was a major risk factor for mortality from COPD. 
Subsequent longitudinal studies have shown accelerated 
decline in the volume of air exhaled within first second of the 
forced expiratory maneuver (FEV1) in a dose dependent  
manner to the intensity of cigarette smoking, which is typically 
expressed in pack years (average number of packs of cigarette 
smoked per day multiplied by total number of years of 
smoking). 
                                    This dose – response  relationship 
between reduced pulmonary function and smoking intensity 
accounts for higher prevalence rate of COPD with increasing 
age. The historical higher rate of smoking among male is the 
likely explanation for higher prevalence of COPD among male. 
However the prevalence rate of COPD among women is 
increasing as the gender gap in smoking rates is diminishing 
globally in the past 50 years.  
            COPD includes all of the following clinical labels 
namely,13 
1. Chronic bronchitis 
2. Emphysema 
3. Chronic airway obstruction 
4. Chronic non-specific lung disease 
5. Non-reversible obstructive airways  disease 
6. Small airway disease( obliterative 
bronchiolitis) 
7. Cases of chronic asthma with fixed airway 
obstruction 
 INDIAN SCENARIO   
                                       In India COPD is the second most 
common lung disorder, the first being pulmonary tuberculosis. 
COPD  most commonly affects people of middle age. It is rare in 
patients < 35 years of age. In India male are affected more than 
the female. This could be due to difference in smoking habits 
among the Indian population. The prevalence of the disease in 
equal in both urban and rural population.  In rural areas 
disease prevalence is mainly due to unchecked smoking 
practices among the uneducated people, especially smoking 
beedies.  In urban area, smoking with superimposed exposure 
to dust, fumes and industrial particles predispose to COPD.                            
 
DEFINITION 
                             The American Thoracic society defines 
chronic obstructive pulmonary disease as a disease state 
characterized by the presence of airflow obstruction due to 
chronic bronchitis or emphysema; Airway obstruction is 
generally progressive, may be accompanied by airflow 
hyperreactivity, and may be viewed as partially reversible. 
                                COPD is usually diagnosed by 
demonstration of irreversible airflow limitation. Most groups 
such as the American Thoracic Society (1987), and the 
European Respiratory Society (1995), specifically excluded 
asthma. However American Thoracic Society (1995) guidelines 
included asthma with an irreversible component within COPD. 
Some studies mean COPD as smoking related chronic airway 
disorder2,3.  While others include all disorders causing chronic 
airway obstruction (eg. Bronchiectasis and obliterative 
bronchiolitis).4,5  
                                Recent data has suggested that COPD is a 
complex and heterogenous disorder with a number of different 
pathological processes leading to recognition of subgroups that 
may have their own characterisations and natural history.6   
 The Dutch hypothesis originally put forward by Orie et al 
proposed a unitary hypothesis for all chronic airway disorders 
which included chronic asthma and COPD were due to 
constitutional disturbance, airway hyper-responsiveness (AHR) 
and atopy.7   However, as most workers considered asthma and 
COPD are different entities and COPD was considered to be due 
to an exogenous factor   i.e. smoking, Dutch hypothesis was not 
accepted. 
                    Although the attributable risk of tobacco smoking 
to COPD is about 85-90%8, only 15% of smokers develop COPD. 
Polymorphism for the genes controlling xenobiotic metabolism, 
hence oxidant-antioxidant balance may explain this 
susceptibility.9,10   About  10-15% of COPD have been thought 
due to other risk factors like environmental tobacco smoke 
(ETS), occupational exposures and genetic factors. Causal 
association between COPD and passive smoking requires 
additional evidence, as the magnitude of association is small.8  
          Recently  COPD is defined more clearly using the 
following clinical diagnostic criteria.11                 
1. History of chronic progressive symptoms  like cough 
and / or wheeze and /or breathlessness. 
2. Objective evidence of airway obstruction i.e. FEV1 
<80% predicted and FEV1/FVC <70% which is 
irreversible. 
3. Usually a smoking history of more than 20 pack years. 
                         Milder forms of chronic bronchitis may be 
relatively asymptomatic with only cough due to mucus 
production and normal airflow called “chronic simple 
bronchitis”.12  Most patients with chronic bronchitis do not 
have airflow obstruction and hence do not have COPD.   
However 10-15% of smokers are susceptible to more rapid 
decline in airflow than normal. 
                               Emphysema  is defined in anatomic terms – 
abnormal permanent enlargement of gas exchanging units of 
the lung  in association with destruction of alveolar walls and 
without obvious fibrosis. The predominant physiological 
consequences of these anatomical abnormality is a decrease in 
elastic recoil of the lung – which in turn causes outward 
displacement of the chest wall, flattening of the diaphragm, 
hyper inflation of the lungs and increased resistance to airflow 
due to circumferential traction on the small airways by the over 
distended lung. 
                                       As a rule clinicians believe that they 
can identify most patients with atopic or extrinsic asthma  that 
begins in childhood and those with  intrinsic asthma of middle 
age. The characteristic features are reversibility of airflow 
obstruction and hyperresponsiveness of the airways to diverse 
inciting influences. In asthma the larger bronchi are 
predominantly affected, goblet cells undergo hyperplasia, 
bronchial glands hypertrophy, the basement membrane 
thickens, airway smooth muscle hypertrophies and the walls 
and lumina are invaded by eosinophils. 
                           Localized  bronchiectasis  is often present in 
patients with COPD. As a rule, however, bronchiectasis is 
characterized by dilatation of airways rather than narrowing.  
Bronchiectasis  does not contribute to obstruction of airflow. 
Characteristically, proximal airways are dilated and distal 
airways are obstructed by mucopurulent  exudate  and by 
narrowed obliterated terminal airways.                
                              In a recent study O’Brien and colleagues 
evaluated cases admitted as acute exacerbation of COPD with 
full lung function and high resolution CT after they were 
clinically stable. An interesting finding of the study was that 
evidence of bronchiectasis was present in 29% of the cases 
suggesting  that CT scanning may play an important role in 
defining the exact nature and subgroup of COPD. 
                               Obliterative bronchiolitis or constrictive 
bronchiolitis is a specific cause of chronic airway limitation and 
is due to small airway obstruction. The term small airway 
disease was coined by Hogg et al 14 and consists of involvement 
of the peripheral airways. Small airways are those less than 3 
mms in diameter most of which are respiratory bronchioles. 
They have a large cross sectional area and hence contribute 
very little to airways resistance, also called the silent zone of the 
lung. 
                  A recent epidemiological study13 on prevalence of 
COPD in spain used spirometric criteria for diagnosis. 
Irreversible airway obstruction was seen in majority of the cases 
( 74 .1%), though 21.7% of cases had good reversibility of 
airway obstruction after bronchodilator test. The prevalence is 
reported as 15% in smokers, 12.8% in ex-smokers and 4 .1% in 
non-smokers. 
RISK FACTORS  
 There are numerous risk  factors for COPD. It includes, 
increasing age27, male gender, smoking habits, environmental 
pollution, socioeconomic status, genetic factors like alpha1 
antitrypsin defieciency, birth weight and childhood respiratory 
illness, recurrent bronchopulmonary infections. Of these 
smoking is associated with 85-90% of COPD cases. Yet  three 
points  about disease occurrence is to be stressed. First, with 
exception of smoking and alpha1 antitrypsin deficiency, the 
mechanism by which the risk factors cause COPD is not at all 
clear. Second, even with smoking which carries the highest 
risk, it is not possible to predict which person will actually 
develop COPD. Third,  even though smoking and  alpha1 
antitrypsin deficiency dominate as risk factors, there are 
definitely other risk factors for developing COPD. Low 
socioeconomic status is one such risk factor22. 
EPIDEMIOLOGY  
                    COPD occurs worldwide, but is a major health 
problem principally in societies where cigarette smoking is 
common and average lifespan extend into the fifth decade and 
beyond. In  western population it is  the fourth most common 
cause of death and the death percent accounted for about 4.5% 
of all deaths.    
                     In 1995, in the developed countries  2 million 
death were due to tobacco and in developing countries  it could 
be 1 million. By 2020 it is likely to increase to 3 million and  7 
million in developed and developing countries respectively 24.   
                         In a meta analysis by Halbert RJ et al30,  the 
prevalence of COPD was 7.5% , the prevalence of chronic 
bronchitis was 6.4% and that of emphysema was 1.8%. 
prevalence of COPD by spirometric estimates was 8.9%. 
SMOKING  AND DISEASE PATTERN  
                   Smoking usually begins for psychological reasons, 
such as curiosity, parental smoking, peer pressure, 
rebelliousness, and assertion of independence. 
                               Pattern of smoking is different in 
developing and developed countries.  
                             In developing countries over 50% men smoke 
while only 10% of women smoke, compared to developed 
countries where 25-30% of both men and women smoke. 
 
 
SMOKING  AND DISEASE ASSOCIATIONS 
           Smoking increases the absolute number of deaths  from 
lung cancer, cancer of other respiratory sites, chronic 
bronchitis/ emphysema and cor pulmonale.  Death from lung 
cancer is 8-25 times more common among smokers  with a 
clear dose-response relationship 
                               Death from IHD and cerebrovascular 
disease are advanced by smoking without an increase in 
absolute number. 
.              Smoking is also associated with gastro intestinal 
diseases like peptic ulcer disease, gastro esophageal reflux, 
chronic pancreatitis, crohns disease, colonic adenomas. 
                It can cause reproductive disease like  ovarian 
failure, decreased sperm quality, pregnancy related events like 
spontaneous abortion, prematurity, fetal effects like low birth 
weight, SIDS, impaired lung growth, atopy and asthma. 
              It can also be related to renal diseases like 
glomerulonephritis, and others such as benign prostatic 
hypertrophy, cataract and peripheral vascular disease.    
SMOKING   AND COPD                 
Nearly all patients with clinically significant 
emphysema are smokers. Smoking is also a major risk factor 
for chronic bronchitis. Heavy smokers are at greater risk of 
developing COPD, than moderate smokers.  Low exposures to 
cigarette smoke as encountered during passive smoking also 
seem to be harmful. 
                          Fletcher and Peto16 showed that smoking was 
associated with irreversible obstructive changes in airways in 
some subjects while not in others. 
                          Sandvik et al17  described the long term effects 
of smoking on pulmonary function through his longitudinal 
study in 1393 middle aged  Norwegian males and followed up 
the patients for about 7 years. The study stated that smoking is 
definitely associated with increased risk of COPD. But other 
factors also determine its predisposition. 
                          Marcus et al18 described that smoking causes 
decline in pulmonary function in dose dependent manner and 
cessation of smoking improves the obstructive pattern.           
                             On an average, the rate of expiratory airflow 
in smokers decrease twice as fast in smokers (40 ml per year) 
as in non- smokers( 20ml per year). 19 
                                  Nonetheless, most smokers do not 
develop symptomatic COPD, probably because of the large 
physiological reserve of the lung. However some smokers (15%) 
do experience accelerated loss of lung function and develop 
symptomatic disease. The basis of the heightened susceptibility 
in this group is not known. 
                          The degree of cough,  phlegm and wheeze are 
directly related to number of cigarette smoked daily. The tar 
yield in the cigarette is related to the  volume of sputum 
production.20 
                            Smoking  in early stages apart from causing 
cough and wheeze, reduces the exercise tolerance. Reduction in 
exercise tolerance is aggravated by high levels of 
carboxyhemoglobin 21  
PATHOPHYSIOLOGY 
                                Many pulmonary function abnormalities 
occur in COPD. Increases in residual volume, and  the residual 
volume to lung capacity ratio, non uniform distribution of 
ventilation and ventilation perfusion mismatch are also typical 
findings but, persistent  reduction in forced expiratory flow 
rates is the most typical finding.  Reduction in FEV1 and 
FEV1/FVC are the characteristic physiological abnormalities of 
COPD.  
                      Airflow during forced exhalation is the result of 
balance between the elastic recoil of the lungs promoting the 
flow and the resistance of the airways limiting the flow. The 
relative contribution of diminished elastic recoil and increased 
resistance in reducing maximal expiratory airflow can be 
quantified  from the flow – pressure curves. With decreased 
elastic recoil, the curve has a normal slope, but it terminates 
prematurely. In contrast, with increased airway resistance the 
slope becomes less steep, reflecting the necessity for increased 
driving pressure for   any level of airflow. 
                                Though there is considerable variability in 
the relationship between the fev1 and other physiological 
abnormalities in COPD, certain generalisations can be made. 
The arterial Po2  (Pao2),    usually remains near normal until the 
FEV1 is decreased to about half of the predicted value. Even  a 
much lower FEV1 may be associated with normal Pao2, atleast 
at rest.  An elevation of  Paco2 is not expected in COPD until the 
FEV1 is less than one-fourth of the predicted value.  
PATHOGENESIS 
                            COPD is characterized by mild chronic 
inflammation throughout the airways, lung parenchyma and 
pulmonary vasculature.22     
Various proposed hypothesis for   COPD are 
                     1. Inflammatory repair hypothesis 
                     2. Proteinase  anti-proteinase hypothesis 
 
 
INFLAMMATORY REPAIR HYPOTHESIS 
                Cigarette smoke is made up of 92% vapourised 
chemicals and 8% particulate materials. These chemicals and 
particulate materials, attract the various inflammatory cells 
that play an important role in the pathogenesis. 
Neutrophils, macrophages and CD8+ lymphocytes 
are the major  cells involved  in the inflammatory 
response in COPD patients. Smoking plays a major role in 
producing such inflammatory reaction in the airways and 
lung parenchyma.                                                              
                                Smoking recruits macrophages, 
neutrophils and lymphocytes and these cells are increased in 
various parts of the lung. The inflammatory cells get activated 
and initiate the inflammatory process through various 
mediators. 
                           Activated inflammatory cells release a variety 
of mediators including Leukotriene B4, IL-8, TNF and others 
capable   of damaging lung structure or sustaining neutrophil 
inflammation. 
                             Any stimulus that increases either the 
number of leukocytes ( neutrophils, macrophages ) in lung or 
release their elastase  containing granules, increase the 
elastolytic activity thereby triggering a chronic inflammatory 
response in the lung. 
                            Stimulated neutrophils also release oxygen 
free radicals that inhibit alpha1 antitrypsin. With low levels of   
alpha1AT, the elastic tissue destruction is unchecked leading to 
emphysema, a form of chronic obstructive pulmonary disease. 
                         In smokers, neutrophils and macrophages 
accumulate in the alveoli and pathogenesis may involves the 
following processes. 
          ● Direct   chemoattractant effects of nicotine  and also 
due to the effects reactive oxygen species in smoke 
           ● Accumalated neutrophils are activated and release their granules 
rich in variety of their cellular proteases ( Neutrophil elastase, Proteinase 3, 
Cathepsin G).  
           ● Various cellular proteinases released cause tissue 
destruction. 
           ● Smoking enhance the elastase activity of the macrophages. 
           ●  Macrophage  elastases are not inhibited by alpha 1 AT and hence the 
elastase activity is unchecked causing tissue destruction. 
           ● Matrix metalloproteinases from neutrophils and macrophages also 
play an important role in tissue destruction. 
          ● Oxidant and  anti-oxidant balance is essential and smoking disturbs it 
causing an imbalance, once again predisposing to tissue destruction. 
          ●   Normal   lung  contain a  lot  of  anti-oxidants  like  SOD, 
Glutathione that keep oxidative damage at minimum. 
          ●  Tobacco smoke contain an abundant reactive oxygen species  ( Free 
radicals) that deplete these anti-oxidant mechanism thereby inciting tissue 
damage. 
            ●   Secondary consequence of oxidative injury  is inactivation of 
native anti - proteases resulting in functional alpha1  anti- trypsin deficiency 
even in patients without enzyme deficiency.    
PROTEINASE ANTI-PROTEINASE HYPOTHESIS 
                    According to this theory there is steady and 
episodic release of proteolytic enzymes into the lung 
parenchyma. Normally, plasma proteinase inhibitors, especially 
alpha1 anti-trypsin, permeate lung tissue and prevent the 
proteolytic enzymes from digesting the structural proteins of 
the lung. The uninhibited activity of proteinases cause 
destruction of the Elastin in the lung parenchyma which is the 
key event in the development of emphysema. Elastin is the 
principal component of elastic fibers, which are prominent part 
of lung’s extra cellular matrix.  
                  
                  Elastin is secreted as a soluble  protein of 60 to 70 
kDa called tropoelastin, encoded by gene on chromosome 7. 
Tropoelastin molecules are deposited into the extra cellular 
space and aligned on a scaffolding of microfilaments consisting 
of number of proteins like fibrillin, microfibril associated 
protein. Elastin synthesis in the lung begins in the late fetal life 
and stops in adult life. Destruction of the lung elastin plays an 
important role in the pathogenesis of emphysema. 
 
COMPLICATIONS 
• Secondary erythrocytosis 
• Recurrent acute exacerbations 
• Pneumothorax 
• Chronic and acute on chronic respiratory failure 
• Pulmonary hypertension 
• Chronic Cor Pulmonale 
• Right ventricular failure 
• Weight loss 
 
TREATMENT FOR ACUTE EXACERBATION 
   1.  Oxygen therapy 
   2. Bronchodilator- nebulised salbutamol (5mg) or terbutaline 
(10mg) + ipratropium 500µg 
   3.  Corticosteroids – inhaled, in severe cases parenteral 
steroids. 
   4.   Diuretics 
   5.  Antibiotics 
    6.  Respiratory stimulants like Doxapram 
    7.  Chest physiotherapy 
    8.  Mechanical ventilator –  Non invasive positive 
pressure ventilation is the procedure of choice 
TREATMENT FOR CHRONIC COPD 
 1. Smoking cessation 
 2. Avoid dusty environment 
3. Bronchodilator 
4. Steroids 
5. Theophylline or aminophylline 
6. Cilomilast31 is an orally active phospho diesterase inhibitor-4 
and is effective in reducing the exacerbations and maintaining 
lung function.  
SMOKING CESSATION 
                   Nicotine is the active psychopharmaceutical drug 
contained in the leaves of tobacco plant. Nicotine is a potent 
euphoriant. On   a molar basis nicotine is more active than 
euphoria inducing drugs such as cocaine, amphetamine and 
morphine. 
                      Nicotine has number of other effects on CNS. It 
may improve task performance and attention time, measurably 
in non habituated subjects. It may also alleviate anxiety and 
depression and induce a sense of well being, while causing a 
state of arousal. Unfortunately nicotine is also an addicting 
substance. 
                     Smoking is a major public health problem. Health  
hazards attributable to smoking parallel smoking prevalence. 
Hence smoking cessation is very important for reducing the 
disease burden of COPD which is the fourth most common 
cause of death worldwide. Smoking cessation can be attained 
by 
1. Non pharmacological methods 
2. Pharmacological 
Non pharmacological methods involve various behavioral 
techniques. 
PATIENT EDUCATION – If smokers could be educated about 
health hazards of cigarette smoking, they could theoretically 
become motivated and psychologically empowered to quit. 
Unfortunately, the anticipated benefits were not obtained. 80% 
smokers indicate that they want to quit but could not. 
HYPNOSIS is to enable the smokers to achieve an altered state 
of consciousness that enhances the ability to quit. However, it 
is of low reliability with published qui rates between 0 and 88%. 
ADVERSIVE CONDITIONING  is extinguishing smoking by 
associating it with negative sensation like electric shock, 
nausea inducing drugs, hot, smoky air treatment. It is of 
limited value. 
GROUP COUNSELING  offered by several commercial and 
voluntary health organizations. It typically include lectures, 
group interaction, some form of tapering method like quit a day 
development of coping skills. This method is largely limited to 
cities and one year success rate ranges between 15-35%. 
PHARMACOLOGICAL METHODS  
It includes tranquilizers, antidepressants, topical anaesthetics, 
anti anxiety agents, anti cholenergics, clonidine and nicotine 
replacement therapy. 
Lobeline sulphate is pharmacologically similar to nicotine and 
was selected as stop-smoking drug. Interest in it has declined 
but recently sublingual formulation are being tested. 
Amphetamine is similar to nicotine and cause euphoria. Once 
thought of promising drug, now proved to be of  little value. 
   Bupropion, originally developed as anti depressent is very 
useful in nicotine deaddiction.  
Nicotine replacement therapies   
             Nicotine replacement therapy dates back to 1950s in 
the form of lozenges. Today  there are several forms of nicotine 
replacement therapy available, including nicotine polacrilex, 
Transdermal nicotine, nicotine nasal spray, nicotine vapours 
and aerosols, and nicotine toothpicks. Two widely adopted 
therapies are  
1. Nicotine polacrilex -  Nicotine is bound to a resin and is 
available in two doses of 2mg and 4mg. Blood nicotine 
levels are less than 40%  associated with customary 
smoking. It is proved to be effective in reducing the 
nicotine withdrawal symptoms. 
2. Transdermal nicotine – primary advantage of transdermal 
delivery system is ease of use and controlled drug delivery. 
They reduce withdrawal symptoms and studies have 
proved that abstinence associated with transdermal patch 
is double that of placebo.26 
 
 
GUIDELINES FOR ENDOTRACHEAL INTUBATION 
1. Persistent hypoxemia with failure to maintain Pao2 55-
60mm of Hg or oxygen saturation <88-90% despite 
maximum medical treatment 
2. Worsening respiratory acidosis 
3. Signs of progressive respiratory muscle fatigue 
4. Deterioration of mental status  
5. Inability to protect airway  
6. Inability to clear copious secretions. 
.  
 PATIENTS AND METHODS 
PLACE OF STUDY 
 This study was conducted in the general medical ward of  
Government  Kilpauk  medical college Hospital, Chennai. 
PERIOD OF STUDY 
 From   April   2004  to  February  2005. 
DESIGN 
 Observational prospective cohort study of patients who 
are smokers admitted in the hospital for complaints other than 
respiratory symptoms. A total of 100 patients were included in 
the study. 
METHODOLOGY 
A. Subject selection 
1. Inclusion criteria 
 a. Subjects randomly selected from medical ward in 
age group    20 -60 years.  
 b. with h/o smoking of atleast one pack year(ie.. > 10 
cigarettes or 15 beedies per day for atleast one year). 
 
2. Exclusion criteria 
 a. Patients who had symptoms as per American 
Thoracic Society scale for  dyspnoea 
 b. Known case of cardiac disease. 
 c. Known diabetic patients. 
 d. Patients with spinal deformity. 
e.       Age > 60 years 
All patients included in the study were subject to thorough 
clinical examination. All were subject to laboratory investigation 
as per the proforma. 
                   After the investigations, patients were subjected to 
spirometry in medical department, kilpauk medical college, 
Chennai by using FUKUDA SANGYO spirometer and results 
were recorded and analyzed. 
FUKUDA SANGYO 
The spirometer used was FUKUDA SANGYO. This spirometer 
can measure and analyze the pulmonary function by means of 
Fleish type flow sensor and variable reluctance type transducer. 
          The readings were calculated according to Indian 
population by a formula devised by Udwadia et al ., which is as 
follows:  
 
UDWADIA’S  FORMULA 
VARIABLES               MALE                            FEMALE 
FEV 1(L)      Adults <30years                       Adults <30years  
                     0.039×H-0.010 × A-3.266        0.025× H-0.011 × 
A-1.424 
                    Adults >30years                       Adults >30years 
                     0.037×H-0.022× A-2.650         0.032×H-0.012×A-2.580 
FVC(L)        Adults <30years                       Adults <30years 
0.055×H+0.019×A-6.058          0.030×H+0.006×A-2.284 
                     Adults >30years                       Adults >30years 
                    0.054×H-0.018×A-4.832            0.043×H-0.010×A-3.755 
PEF           0.085×H-0.0187×A-6.2083     0.0497×H-0.0336×A-0.1399 
FEF25-75%   0.0173×H-0.0407×A+               0.0245×H-0.0336×A0.1399 
1.6108 
FEF50         0.0195×H-0.0365×                 0.0272×H-0.279×A-0.2704      
                       A+1.7383  
FEF75      0.0088×H-0.0301×A+1.0402   0.0113×H-0.0288×A+0.5012 
 
                                                  A       -    Age in years 
                                                  H      -     Height in cms 
 Interpretation  
                The spirometric readings are useful in the 
interpretation of pattern of pulmonary dysfunction 
 Various abnormalities are 
1. Obstructive pattern 
FEV1     < 70% 
FVC 
2.  Restrictive pattern 
FEV1     > 80% 
FVC 
In normal subjects a full VC may be expired in 3 seconds and a 
slow VC equals FVC.  So   %FVC is taken for grading 
restriction.  
Normal                             > 80% 
Mild restriction               ≥66 - 80% 
Moderate restriction       ≥50 - 65% 
Severe restriction             <50% 
3.   Mixed pattern      
When  both  FEV1/ FVC < 70% and %FVC< 80%  are 
present. 
All datas obtained were statistically analyzed and their 
significance studied. 
                    However, patients cooperation, standardization 
of the  equipment  and the procedure are crucial for any 
meaningful interpretation. It is also important to calculate 
the percent predicted values based on regression equations 
drawn from the population to which the patient belongs. 
From tropical countries like India there are large number of 
reports on normal spirometric values which can be used for 
prediction. 
                           A value less than the lower limit of normal 
can be considered normal provided the technique is 
standardized and the measurement well judged. 
                         The technician is required to calibrate the 
spirometer to a given standard daily before subjecting any 
patient to spirometric test. Each patient’s anthropometric 
data in terms of age, sex, height, and weight entered in the 
computer. The machine is corrected for ambient temperature 
and pressure. 
                                 The patient is then connected to the 
spirometric tubing using a mouthpiece and all leaks around 
the   mouthpiece are seen to be occluded. 
                                 Nasal leaks are prevented by occluding 
the nose with nasal clips. 
                   The patient is then asked to breathe normally in 
the spirometer circuit for a couple of breathes and then 
patient is asked to take maximum inspiration and stop. Then 
patient is instructed to expire forcefully through the  
mouthpiece. 
                         The computer   analyzes these flows and 
volumes in flow-volume and volume-timed formats to give 
results comparing them with the normal predicted values. 
Spirometry can find VC, FVC, FEV1, FEV1/FVC, FEF 25-75%. 
                                Clinical spirometry detects obstructive 
lung disease by measuring dynamic flow rates. It identifies 
whether flow obstruction is present or not, and characterizes 
whether the obstruction is inspiratory,  expiratory or both. 
                                     It provides an objective record of the 
degree of obstruction to aid the prognosis and therapy. It 
grantifies the stage of the disease with broad limits of mild, 
moderate and severe. 
                                 General rule, expiratory flow rate  < 
70% of predicted normal value of FEV1/FVC ratio is 
suggestive obstructive lung disease.  All the values obtained 
were statistically analyzed. 
GOLD classification of COPD 
STAGE                                   CHARACTERISTICS 
0 : at risk                                Normal spirometry 
I : mild COPD                        FEV1/FVC <70% 
                                                FEV1 ≥ 80% predicted  
II : moderate COPD               FEV1/FVC <70% 
                                                30% ≤ FEV1 < 80% predicted 
III: severe COPD                    FEV1/FVC <70% 
                                                 FEV1 < 30% predicted OR   presence of 






 RESULTS AND ANALYSIS 
                     In this study, 100  patients  admitted  for other 
complaints were selected according to inclusion criteria and 
studied.  
DETAILS OF STUDY POPULATION 




AGE GROUP   
(YRS) 
NUMBER PERCENTAGE  
    20 – 29          17          17% 
    30 – 39          24          24% 
    40 – 49          29           29% 
    50 – 60          30          30% 
    TOTAL         100           
  Maximum number of cases studied in age group 50 – 60 (30%) 











TABLE – 2 
SEXWISE DISTRIBUTION  
S.No. Sex Number Percentage 
1. Male 97 97% 
2. Female  3 3% 
 
 













                       Patients  of varied occupation were studied . 
Among them most of them belonged to the group of agricultural 
workers 
TABLE -3 
           CASES         PERCENT  
  FARM  WORKERS              52               52 
 MANUAL 
LABOURERS 
             14               14 










                                          The remaining (others group) 
patients comprised of factory workers, mansons, butchers etc.,   
 
TABLE – 4 





0 -5 6 6 
5 – 10 38 38 
10 – 15 20 20 
>15 36 36 
 
  
          Most of  the patients  (38%) belonged to 5-10 pack years 





















TABLE – 5 
DISTRIBUTION OF SMOKERS 
TYPE CASES % 
CIGARETTE 10 10 
BEEDI 72 72 








TABLE – 6 
BEEDIES CONSUMPTION 
NUMBER OF 
PACKS PER DAY 
CASES % 
1 24 24 
2 54 54 
3 16 16 
>3 6 6 
  












1 2 3 >3
 
Other habits 
74% were alcoholic, usually combined with smoking beedies 
 
GENERAL EXAMINATION 
                   The general examination of the patients showed  
the following abnormalities. Of the 100 cases studied,   38 














TABLE  - 7 
RESPIRATORY RATE RANGE 
RESPIRATORY 
RATE 
      CASES      PERCENT 
        14 – 18               36                36 
        19 -22               20                20 













 TABLE  - 8 
RESPIRATORY SYSTEM EXAMINATION 










RHONCHI 16 16 






 TABLE – 9 
 CHEST CIRCUMFERENCE  
       CHEST      
EXPANSION 
          CASES       PERCENT 
        2.5 -3.5                32                 32 
        3.5 – 5                58                 58 










 TABLE - 10 
HAEMOGLOBIN 
Hb% cases PERCENT 
<10 6 12 
10 – 14 40 80 




TC          CASES       PERCENT 
< 6000                 1                 5 
6000 – 10000                 60                 60 
10001 – 14000                 36                 36 





ESR   VALUES 
Out of the 100 cases studied , 42 had  ESR 6-10/ hr 
                                                  58 had  11- 30/ hr 
Random blood sugar, blood cholesterol, and serum creatinine  
were in normal range. 
PCV  values – none had polycythemia. 
 
CHEST X-RAY 
 It was normal in most of the patients ( 94%). 
6  patients had early emphysematous changes. 





NORMAL EXPECTED SPIROMETRIC VALUES IN 
INDIA (MEAN + SD) 
 
Male 15-19 20-24 25-34 35-44 45-54 >55 
FVC 3.49±0.57 3.65±0.53 3.59±0.54 3.31±0.62 3.14±0.65 2.98±0.67 
FEV1 3.04±0.52 3.09±0.51 2.9±0.47 2.6±0.53 2.42±0.42 2.35±0.51 
FEV1/FEC% 87.1±11 84.6±7 80.6±9 78.4±10 72.4±10 68.9±9 
PEFR 530±72 553±72 559±87 512±98 471±91 451±102 
 
 
Female 15-19 20-24 25-34 35-44 45-54 >55 
FVC 2.46±0.47 2.42±0.52 2.31±0.42 2.24±0.4 1.98±0.44 1.4±0.28 
FEV1 2.08±0.42 2.07±0.45 1.85±0.41 1.75±0.54 1.64±0.3 1.23±0.28 
FEV1/FEC% 85.4±15 85±17 84.5±12 82.9±12 84±10 87±23 






32   Patients showed combined defect ( both restrictive and 
obstructive) 
46 Cases showed obstructive pattern 
8     cases showed restrictive  pattern 






Both Obstr Restr Normal
 
 
FEV1    EXPECTED VS ACTUAL 
AGE 
GROUP   
(YRS) 
EXPECTED ACTUAL PERCENTAGE 
    20 – 
29 
  2.99±0.49        2.38           79% 
    30 – 
39 
  2.7±0.47        1.99           73% 
    40 – 
49 
  2.51±0.51        1.32           53% 
    50 – 
60 
  2.34±0.49        1.01           43% 
    MEAN      2.56        1.67                   
 
The expected  FEV 1 among subjects studied was 2.51± 0.42 L,   
however,     the actual mean  FEV 1 was  1.67± 0.5 L,   65.2%  of the 
expected value. 









20-29 30-39 40-49 50-60
 
FEV1 % 
STAGES OF FEV1          CASES        PERCENT 
       > 80%              18             18 
        60-80%              22             22 










FEV1 % AND PACK YEARS 
      PACK YEARS              FEV1% 
             0-5                 81% 
            5-10                 71% 
            10-15                 49% 


















DISTRIBUTION OF CASES ACCORDING TO  FEV 1/FVC% 
 
FEV1/FVC          CASES       PERCENT 
        >80               34                 34 
        60 – 80               34                 34 
        40 – 60               32                 32 
        < 40                0                  0 
 










DISTRIBUTION OF CASES ACCORDING TO  FEF25-75% 
 
VALUES          CASES        PERCENT 
       > 80              8              8 
      60 -80              18             18 










 FEF25-75%  is a  good indicator of small airway disease. 
The mean value is 49.04% 
 
GENDER DIFFERENCE 
 MALE FEMALE 
FEV 1 1.01(39%) 0.92(43%) 












                               In this study, a major group of patients 
46%  showed obstructive pattern, 32% showed mixed 
pattern, 8% showed restrictive pattern and 14% had normal 
lung function. 
                               In a similar study by Zielensky.J et al27., 
spirometric analysis, airway limitation was observed in 
20.3% patients and restrictive pattern was observed in 8.3% 
patients comparable to this study. 
                         In this study, though patients did not 
complain  subjective respiratory symptoms, 10 patients had 
clubbing. In the present study, decreased chest movement 
was seen in 12% patients, decreased breath sounds in 18% 
and barrel shaped chest was seen in 8% subjects. In a 
similar study by K.V.Thiruvengadam et al., decreased chest 
movement, decreased breath sound, and barrel shaped chest 
were seen in 50%, 43.3% and 16.7% patients.  
                            An important finding in this study is that 
88% patients had reduced FEF25-75%    and 74% showed 
significant fall in FEF25-75% < 60%.   FEF25-75%   is a very good   
indicator of small airway disease. Statistically the percentage 
of reduction   occurred in 88% of patients which is 
significant. 
                        Hogg et al14 made a finding of major 
importance that airways 2 mm or less in diameter contribute 
only a minor part  of the total airway resistance normally, 
but that these airways become the principal sites of 
increased resistance in COPD. This study gave rise to the 
concept that COPD is a small airway disease. 
                       In male, the reduction in forced expiratory 
volume reduction in 1s (FEV1) per year above the normal 
decline in adults for each pack-year of smoking is 9 ml; in 
female the excess rate of decline is about 6 ml. Based  on 
these rates of decline, a man who has smoked one pack per 
year for the past 20 years will have FEV1 that is 180 ml less 
than it would have been if the person had not smoked. In 
this study it is observed that patients with longer duration of 
smoking had much reduced FEV1 than those with shorter 
duration of smoking. 
                      In the present study, there was significant 
reduction in FEV1. The mean  FEV1 was 1.67±0.05 L against 
the expected 2.56±0.49L which was 65% of the expected for 
the age. Reduction in  FEV1 was maximum in the age group 
of 50-60 years  - 43% of the expected and minimum in  20-
29 yrs -79%. 
                           In a study by  Fletcher et al.,16  800 
working men both smokers and non smokers were studied, 
the rate of decline of FEV1 that normally begins by 25 years 
of age, was markedly increased in 10-15 % of susceptible  
smokers. Clinical disability did not occur until late in the 
disease when FEV1 was reduced by about 70% of the 
expected value. This study results may help to explain why 
many patients even when FEV1 was decreased to 60% did 
not have respiratory symptoms like breathlessness. The 
findings of Fletcher’s study have been confirmed  by the 
Lung Health Study.23 
                    The Lung Health Study revealed that among 
middle- aged smokers with FEV1 between 55 and 90% of 
predicted, differences of several hundred ml in FEV1 
developed within five years between those who quit and 
those who did not quit smoking. Such deleterious effect of 
smoking was seen in 10-15% of the susceptible smokers. 
                           The mean FEV1 in this study  was 1.675 L 
and  the expected mean  FEV1 was 2.56± 0.42 L, which is 
65.5% of the expected value. In a similar study  by Vaidya 
PR et al the observed FEV1 was 1.28 ±0.66L. 
                    The mean expected FVC was 3.25 ±0.48L , the 
actual  mean was 1.94 ± 0.64 L which was about 60% of the expected 
value. In Vaidya et al., study observed value was 1.97±0.66 L. 
                         On an average,  the rate of expiratory airflow in 
smokers decrease twice as fast in smokers ( 40ml per year) as 
in non smokers( 20ml per year). 19 
              The small sample of 3% female patients were matched for age 
and smoking habits and it was found that  FEV1 was 0.92L (39%) 
compared to 1.01 (43%) in male subjects.  
               Though definitive conclusion could not be drawn due to small 
sample size, the accelerated decline in fev1 was noted in women than men. 
                  In a study by Gan WQ et al28., it was concluded that women as 
they age, are at increased  risk of accelerated decline in FEV1. In another 
study by Johannessen et al29., sex and residential area did not influence the 
incidence of  COPD.    
 
        Thus spirometry is very useful to detect obstructive 
lung disease by measuring dynamic flow rates. It identifies 
whether flow obstruction is present or not, and characterizes 
whether the obstruction is inspiratory, expiratory or both. It  
thus helps in identifying COPD in early stages so that 













 In this study, 46% patients showed obstructive 
pattern, 32% showed mixed pattern, 8% showed 
restrictive pattern and 14% subjects had normal lung 
function. 
  Eighty eight percent patients had  small airway 
disease as evidenced by decreased FEF25-75. 
 Progressive decline of FEV1 ( more than that of age 
related decline) was observed in asymptomatic smokers 
as the f was 79%, 73%, 53%,and 43% in the age 
groups of 20-29, 30-39, 40-49 and  50-60 respectively. 
 Age, increased quantum of smoking, female gender all 
are compounding factor in obstructive lung disease as 
evidenced by more FEV1 reduction with increasing age, 
increased pack years of smoking. Mean FEV1 was 
65.5% of the expected normal value. 
 Though definitive conclusion could not be drawn, due 
to small sample size, the accelerated decline of  FEV1 
was noted in women than men, as age matched FEV1 
was 39% in women as compared to 43% in men of 
same age. 
 Routine Pulmonary function test in asymptomatic 
smokers is an important investigation to identify early 
obstructive/mixed/restrictive lung disease, lest such 
identified persons could be enrolled for nicotine 
deaddiction. Early nicotine deaddiction if 
contemplated, might play an important role in primary 
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        Case No. 
Name  :   Age :  Sex : 
IP No. :   DOA  :  DOD: 
Address :      Occupation : 
 
FINAL DIAGNOSIS: 
H/o   Hypertension  
H/o   diabetes mellitus   
 
Past History 
IHD  TB  RHD  BA   
Personal History 
   TOBOCCO use: Smoking Beedi/ Cigarette/ pipe / cigar  
                        Quantity 
                         Period                            Other forms 
  Alcohol 
GENERAL EXAMINATION 
Height   Weight  BMI 
PR :   RHYTHM :   CHARECTOR : 
Temperature:                         BP: 
Respiratory rate:                               Type: 
Pallor:                                     Cyanosis:                




   UPPER RESP.TRACT      NONE 
                                              PNS 





Shape of chest:               B/L   Symmetrical / Not 
Trachea   position:       R / Central / L 
Any spinal deformity:       Scoliosis / kyphosis / Normal 
Any chest deformity:    Hollowing / Bulging / Normal 
Movement of chest:     Equal / Not 
Any dilated veins/pulsations:       Present / Not 
Any scar / sinuses :    Present  / Not 
Use of accessory muscles:    Yes / No 
Intercostal retraction:  Yes / No 
Apical impulse:    Visualized / Not 
  
PALPATION 
Tracheal position:     R / Central / L 
Movement of chest:     Equal / Not 







Palpable rales/ ronchi:   Yes / No 
Site  
 
Percussion   
Anteriorly 
     Kronig isthmus 
     Infraclavicular 
     Mammory     
     Liver dullness 5th ICS   Yes / No  
     Traubes area            Tympanic / Not 
     Tidal percussion:  
Posteriorly 
     Suprascapular: 
     Infrascapular: 
     Interscapular: 
     Axillary: 
     Infra axillary: 
  
AUSCULTATION     
   Breath sounds  -     normal / diminished 
  Type  -  Vesicular / Bronchovesicular / Bronchial 
  Added sounds  - rales / rhonchi 
   Site : 





Investigations   : 
Blood Sugar   :   URINE : 
Serum Creatinine    :    
CXR PA                       : 
ECG     : 
Echo    : 
Spirometry                     : 
Others 
     Bronchoscopy 
     HRCT 
      































No. IP No. Age Sex occupation 
Duration of 
smoking FEV1% FEC1/FVC FEF25-75% 
1 107402 23 1 2 1 1 1 1 
2 107569 30 1 1 2 1 1 2 
3 107600 26 1 1 2 1 1 2 
4 107771 38 1 3 2 1 1 1 
5 107772 57 1 1 4 3 3 3 
6 107974 24 1 1 1 1 1 1 
7 108064 58 1 2 4 3 3 3 
8 107984 46 1 1 3 3 2 3 
9 108411 49 1 3 3 3 3 3 
10 108481 39 1 1 2 2 1 3 
11 108492 60 1 1 4 3 3 3 
12 108596 31 1 2 2 1 1 1 
13 108730 40 1 3 2 2 1 3 
14 109025 59 1 1 4 3 2 3 
15 109026 54 1 1 3 3 2 3 
16 109137 59 1 2 4 3 3 3 
17 109146 41 1 1 3 3 2 3 
18 109289 42 1 1 3 3 3 3 
19 109349 44 1 3 3 3 2 3 
20 109360 53 1 2 4 3 3 3 
21 109681 51 1 1 4 3 2 3 
22 109779 59 1 1 4 3 3 3 
23 109980 42 1 2 2 2 1 3 
24 109984 25 1 1 1 1 1 1 
25 110026 33 1 3 2 2 1 2 
26 110139 57 1 1 4 3 2 3 
27 110163 35 1 3 2 2 1 2 





























29 110260 41 1 1 2 3 1 3 
30 110288 58 1 3 4 3 2 3 
31 110575 36 1 1 2 2 1 2 
32 110585 55 1 3 4 3 3 3 
33 110684 48 1 1 3 3 2 3 
34 110857 53 1 2 4 3 3 3 
35 110870 44 1 1 3 3 2 3 
36 111042 59 2 3 4 3 3 3 
37 111138 35 1 1 2 2 2 3 
38 111542 40 1 3 2 2 2 3 
39 111630 51 1 3 4 3 3 3 
40 111748 28 1 1 2 1 1 3 
41 112044 60 2 3 4 3 3 3 
42 112104 59 1 1 4 3 3 3 
43 112402 49 1 3 3 3 2 3 
44 112455 35 1 3 2 2 1 2 
45 112459 39 1 1 2 2 2 2 
46 112582 29 1 3 2 1 1 1 
47 112586 36 1 1 2 3 3 3 
48 112661 51 1 3 3 3 2 3 
49 112786 56 2 1 4 3 3 3 
50 112911 42 1 1 2 2 2 3 
51 112961 58 1 1 4 3 2 3 
52 113053 31 1 1 2 1 1 1 
53 113211 52 1 1 4 3 2 3 
54 113146 44 1 1 3 3 2 3 
55 113204 58 1 1 4 3 3 3 
56 113284 40 1 1 2 2 1 2 
57 113361 42 1 2 2 2 1 2 
58 113529 37 1 1 2 2 1 2 
59 113619 56 1 3 4 3 3 3 





























61 113800 52 1 2 4 3 3 3 
62 113820 59 1 1 4 3 3 3 
63 113815 43 1 1 3 3 3 3 
64 113828 60 1 2 4 3 3 3 
65 114140 36 1 1 2 2 2 2 
66 114165 27 1 1 2 1 1 1 
67 114263 51 1 3 4 3 2 3 
68 114301 59 1 1 4 3 3 3 
69 114364 40 1 1 2 2 2 3 
70 114424 49 1 3 3 3 3 3 
71 114624 24 1 2 1 1 1 1 
72 114648 51 1 3 4 3 3 3 
73 114653 48 1 3 3 3 2 3 
74 114686 29 1 3 2 1 1 2 
75 115074 60 1 1 4 3 3 3 
76 115092 25 1 1 1 1 1 1 
77 115205 60 1 1 4 3 3 3 
78 115094 45 1 3 3 3 2 3 
79 115291 35 1 1 2 3 3 3 
80 115319 59 1 2 4 3 3 3 
81 115332 26 1 1 1 1 1 1 
82 115555 34 1 3 2 2 1 2 
83 115706 58 1 3 4 3 3 3 
84 115782 41 1 1 2 2 2 3 
85 115783 53 1 3 3 3 2 3 
86 115813 34 1 3 2 2 1 3 
87 115936 53 1 1 3 3 2 3 
88 116013 59 1 3 4 3 3 3 
89 116031 40 1 1 2 3 1 3 
90 116242 30 1 2 2 1 1 3 
91 116463 57 1 3 4 3 2 3 








   SEX: MALE-1; FEMALE-2 
   OCCUPATION: FARM WORKER-1; MANUAL LABOURER-2; OTHERS-3 
   DURATION: 0-5YRS-1; 5-10YRS-2; 10-15YRS-3; >15YRS-4. 
   FEV1 : >80%-1 ; 60-80%-2 ; <60%-3 
   FEV1/FVC : >80%-1 ; 60-80%-2 ; 40-60%-3 ; <40%- 4 
   FEF25-75 : >80-1 ; 60-80-2 ; <60-3. 
93 116977 27 1 1 2 1 1 1 
94 117082 56 1 1 4 3 2 3 
95 117131 39 1 3 2 1 1 2 
96 117135 34 1 3 2 2 1 3 
97 117194 51 1 2 4 3 3 3 
98 117200 41 1 3 2 2 1 3 
99 117218 47 1 1 3 3 2 3 
100 117615 40 1 1 3 3 2 3 
